About Biofire Diagnostics
Biofire Diagnostics is a company based in Salt Lake City (United States) founded in 1990 was acquired by Institut Merieux in December 2021. Biofire Diagnostics has raised $84 million across 6 funding rounds from investors including HHS, BioMerieux and 10X Capital. Biofire Diagnostics offers products and services including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel. Biofire Diagnostics operates in a competitive market with competitors including ChromaCode, Inflammatix, Visby Medical, MeMed and GenMark Diagnostics, among others.
- Headquarter Salt Lake City, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biofire Diagnostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$84 M (USD)
in 6 rounds
-
Latest Funding Round
$14 M (USD), Series A
Nov 07, 2022
-
Investors
HHS
& 10 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biofire Diagnostics
Biofire Diagnostics offers a comprehensive portfolio of products and services, including BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Multiplex PCR system for rapid infectious disease testing.
Detects viruses and bacteria in respiratory samples.
Identifies pathogens in gastrointestinal infections.
Funding Insights of Biofire Diagnostics
Biofire Diagnostics has successfully raised a total of $84M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biofire Diagnostics
Biofire Diagnostics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, BioMerieux and 10X Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and defense sectors.
|
Locked | Locked | Locked | |
|
Access to private investment strategies is provided for institutional investors.
|
Locked | Locked | Locked | |
|
Venture capital investing with a focus on diversity and inclusion in the ecosystem.
|
Locked | Locked | Locked |
Investor details for Biofire Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biofire Diagnostics
Investment portfolio details for Biofire Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biofire Diagnostics
Detailed financials for Biofire Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biofire Diagnostics Comparisons
Peer comparison for Biofire Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biofire Diagnostics
Biofire Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChromaCode, Inflammatix, Visby Medical, MeMed and GenMark Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital molecular biology analytics are developed for disease management.
|
|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
Detailed competitors of Biofire Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biofire Diagnostics
Complete news archive for Biofire Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofire Diagnostics
Biofire Diagnostics was founded in 1990 and raised its 1st funding round 22 years after it was founded.
Biofire Diagnostics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Biofire Diagnostics is a funded company, having raised a total of $84M across 6 funding rounds to date.
Biofire Diagnostics was founded in 1990 and is headquartered in Salt Lake City, United States. Operations center on the molecular diagnostics sector, where new assays are developed for the proprietary FilmArray System, a multiplex PCR platform. Panels offered include Respiratory (RP), Blood Culture Identification (BCID), Gastrointestinal (GI), and MeningitisEncephalitis (ME) tests for pathogen detection.
Biofire Diagnostics's top competitors include ChromaCode, Visby Medical and Inflammatix.
Biofire Diagnostics offers BIOFIRE System, Respiratory Panel, and Gastrointestinal Panel.
Biofire Diagnostics has 11 investors. Key investors include HHS, BioMerieux, 10X Capital, Institut Mérieux, and Gavin de Becker and Associates.